{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:38:19Z","timestamp":1788910699011,"version":"build-2803163510"},"reference-count":119,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Acquired hemophilia A (AHA) is a bleeding disorder characterized by the immunological inhibition of factor VIII (FVIII) of the hemostatic pathway leading to hemorrhagic events. Different domains of FVIII are the target of autoantibodies (mainly immunoglobulin (Ig) G) leading to the deficiency of FVIII. Several factors have been associated with the activation of the auto-immunity towards FVIII. Emerging evidence implicates CD4+ T cell activation in mediating this autoimmune response, with their involvement like that observed in congenital hemophilia A. Several genes such as HLA II DRB*16, DQB1*0502, and CTLA-4 + 49 are responsible for the pathogenesis of AHA. Epigenetic modifications and mainly long-coding RNAS (lncRNAs) are potentially contributing to the pathogenesis of AHA. The treatment approach of AHA includes the management of acute bleeding events and the administration of immunosuppressive medications. This review aimed to summarize the published data on the genetics and epigenetics of AHA. The severity and the mortality of this disease are creating an emerging need for further research in the field of the genetics and epigenetics of acquired hemorrhagic disorder.<\/jats:p>","DOI":"10.3390\/cimb46060309","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T05:35:20Z","timestamp":1716442520000},"page":"5147-5160","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Genetics and Epigenetics in Acquired Hemophilia A: From Bench to Bedside"],"prefix":"10.3390","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0519-1670","authenticated-orcid":false,"given":"Nikolaos","family":"Evangelidis","sequence":"first","affiliation":[{"name":"Hematology Unit-Hemophilia Centre, 2nd Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2919-5179","authenticated-orcid":false,"given":"Nikolaos","family":"Kotsiou","sequence":"additional","affiliation":[{"name":"Hematology Unit-Hemophilia Centre, 2nd Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1783-5111","authenticated-orcid":false,"given":"Paschalis","family":"Evangelidis","sequence":"additional","affiliation":[{"name":"Hematology Unit-Hemophilia Centre, 2nd Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlasios I.","family":"Alevizopoulos","sequence":"additional","affiliation":[{"name":"Hematology Unit-Hemophilia Centre, 2nd Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9134-1083","authenticated-orcid":false,"given":"Iasonas","family":"Dermitzakis","sequence":"additional","affiliation":[{"name":"Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Chissan","sequence":"additional","affiliation":[{"name":"Hematology Unit-Hemophilia Centre, 2nd Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Vakalopoulou","sequence":"additional","affiliation":[{"name":"Hematology Unit-Hemophilia Centre, 2nd Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-8208","authenticated-orcid":false,"given":"Eleni","family":"Gavriilaki","sequence":"additional","affiliation":[{"name":"Hematology Unit-Hemophilia Centre, 2nd Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: Molecular and Clinical Similarities and Differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/a-1945-9429","article-title":"Insights into the Molecular Genetic of Hemophilia A and Hemophilia B: The Relevance of Genetic Testing in Routine Clinical Practice","volume":"42","author":"Pezeshkpoor","year":"2022","journal-title":"Hamostaseologie"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/MBC.0000000000000821","article-title":"Clinical Pattern of Hemophilia and Causes of Variability","volume":"30","year":"2019","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd Edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/hematology.2022000388","article-title":"Gene Therapy for Hemophilia","volume":"2022","author":"Nathwani","year":"2022","journal-title":"Hematology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/biologics4020010","article-title":"Gene Therapy for Hypertension, Atherosclerosis, and Familial Hypercholesterolemia: The Old Concepts and the New Era","volume":"4","author":"Evangelidis","year":"2024","journal-title":"Biologics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.thromres.2016.02.001","article-title":"Understanding Cardiovascular Risk in Hemophilia: A Step towards Prevention and Management","volume":"140","author":"Sousos","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Theodoropoulos, K.C., Vakalopoulou, S., Oikonomou, M., Stavropoulos, G., Ziakas, A., Kanonidis, I., and Kassimis, G. (2021). How to Manage a Patient with Haemophilia and ACS Requiring PCI: A Battle between Bleeding and Thrombosis. Medicina, 57.","DOI":"10.3390\/medicina57040352"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/hae.13427","article-title":"Hepatitis C Infection in a Greek Population with Inherited Bleeding Disorders","volume":"24","author":"Giouleme","year":"2018","journal-title":"Haemophilia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1160\/TH14-12-1044","article-title":"Inhibitor Development in Non-Severe Haemophilia across Europe","volume":"114","author":"Fischer","year":"2015","journal-title":"Thromb. Haemost."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/hae.12284","article-title":"The Role of Arthropathy in the Development of Osteoporosis in Patients with Haemophilia: Do We Need More?","volume":"20","author":"Anagnostis","year":"2014","journal-title":"Haemophilia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1385052","DOI":"10.3389\/fmed.2024.1385052","article-title":"Hematology: The Specialty with a Record Number of New Approvals","volume":"11","author":"Gavriilaki","year":"2024","journal-title":"Front. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/14712598.2022.2002842","article-title":"Hemophilia A Gene Therapy: Current and next-Generation Approaches","volume":"22","author":"Pipe","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40265-023-01901-9","article-title":"Correction to: Efanesoctocog Alfa: First Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1055\/s-0032-1315757","article-title":"Acquired Inhibitors of Coagulation Factors: Part I\u2014Acquired Hemophilia A","volume":"38","author":"Coppola","year":"2012","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zanon, E. (2023). Acquired Hemophilia A: An Update on the Etiopathogenesis, Diagnosis, and Treatment. Diagnostics, 13.","DOI":"10.3390\/diagnostics13030420"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and Clinical Data in Acquired Hemophilia A: Results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"Knoebl","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired Hemophilia A in the United Kingdom: A 2-Year National Surveillance Study by the United Kingdom Haemophilia Centre Doctors\u2019 Organisation","volume":"109","author":"Collins","year":"2007","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.5858\/2000-124-0730-AHIPWH","article-title":"Acquired Hemophilia in Patients with Hematologic Malignancies","volume":"124","author":"Sallah","year":"2000","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.12998\/wjcc.v6.i14.781","article-title":"Acquired Hemophilia A in Solid Cancer: Two Case Reports and Review of the Literature","volume":"6","author":"Saito","year":"2018","journal-title":"World J. Clin. Cases"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e14119","DOI":"10.1097\/MD.0000000000014119","article-title":"Pregnancy-Related Acquired Hemophilia A Initially Manifesting as Pleural Hemorrhage: A Case Report","volume":"98","author":"Qian","year":"2019","journal-title":"Medicine"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Marino, R. (2023). Acquired Hemophilia A: Bleeding Pattern and Hemostatic Therapeutic Strategies. Medicina, 59.","DOI":"10.3390\/medicina59101739"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired Hemophilia A: Updated Review of Evidence and Treatment Guidance","volume":"92","author":"Kempton","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2141.2003.04162.x","article-title":"Acquired Haemophilia: Review and Meta-Analysis Focused on Therapy and Prognostic Factors","volume":"121","author":"Delgado","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"320674","DOI":"10.1155\/2014\/320674","article-title":"Acquired Hemophilia A: A Frequently Overlooked Autoimmune Hemorrhagic Disorder","volume":"2014","author":"Sakurai","year":"2014","journal-title":"J. Immunol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/BF02708439","article-title":"Blood Coagulation Factor VIII: An Overview","volume":"28","author":"Bhopale","year":"2003","journal-title":"J. Biosci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1532\/IJH97.05113","article-title":"Factor VIII Structure and Function","volume":"83","author":"Fay","year":"2006","journal-title":"Int. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2005.12.015","article-title":"The Protein Structure and Effect of Factor VIII","volume":"119","author":"Fang","year":"2007","journal-title":"Thromb. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2009.02005.x","article-title":"Factor VIII and von Willebrand Factor Interaction: Biological, Clinical and Therapeutic Importance","volume":"16","author":"Terraube","year":"2010","journal-title":"Haemophilia"},{"key":"ref_31","unstructured":"LaPelusa, A., and Dave, H.D. (2024). StatPearls [Internet], StatPearls Publishing."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11739-010-0380-y","article-title":"Diagnosis, Laboratory Aspects and Management of Acquired Hemophilia A","volume":"5","author":"Toschi","year":"2010","journal-title":"Intern. Emerg. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International Recommendations on the Diagnosis and Treatment of Acquired Hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct Characteristics of Antibody Responses against Factor VIII in Healthy Individuals and in Different Cohorts of Hemophilia A Patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2147\/JBM.S284804","article-title":"Acquired Hemophilia A: Current Guidance and Experience from Clinical Practice","volume":"13","author":"Pishko","year":"2022","journal-title":"J. Blood Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1055\/s-0037-1614081","article-title":"Sensitization of CD4+ T Cells to Coagulation Factor VIII: Response in Congenital and Acquired Hemophilia Patients and in Healthy Subjects","volume":"84","author":"Reding","year":"2000","journal-title":"Thromb. Haemost."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/00062752-199909000-00008","article-title":"Autoimmune Factor VIII Inhibitors","volume":"6","author":"Pruthi","year":"1999","journal-title":"Curr. Opin. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1111\/jth.15515","article-title":"Predictive Significance of Anti-FVIII Immunoglobulin Patterns on Bleeding Phenotype and Outcomes in Acquired Hemophilia A: Results from the Quebec Reference Center for Inhibitors","volume":"19","author":"Bonnefoy","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/j.1538-7836.2012.04850.x","article-title":"The IgG Autoimmune Response in Postpartum Acquired Hemophilia A Targets Mainly the A1a1 Domain of FVIII","volume":"10","author":"Lapalud","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2298\/SARH10S1064E","article-title":"Acquired Haemophilia Syndrome: Pathophysiology and Therapy","volume":"138","year":"2010","journal-title":"Srp. Arh. Celok. Lek."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1055\/s-0037-1613257","article-title":"Distribution of Th1- and Th2-Induced Anti-Factor VIII IgG Subclasses in Congenital and Acquired Hemophilia Patients","volume":"88","author":"Reding","year":"2002","journal-title":"Thromb. Haemost."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/jth.13304","article-title":"Diagnostic and Prognostic Value of Factor VIII Binding Antibodies in Acquired Hemophilia A: Data from the GTH-AH 01\/2010 Study","volume":"14","author":"Werwitzke","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood-2015-09-672774","article-title":"Anti-Factor VIII IgA as a Potential Marker of Poor Prognosis in Acquired Hemophilia A: Results from the GTH-AH 01\/2010 Study","volume":"127","author":"Tiede","year":"2016","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/blood-2016-11-751347","article-title":"Frequency and Epitope Specificity of Anti-Factor VIII C1 Domain Antibodies in Acquired and Congenital Hemophilia A","volume":"130","author":"Kahle","year":"2017","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1182\/blood.V89.10.3663","article-title":"The Inhibitor Antibody Response Is More Complex in Hemophilia A Patients than in Most Nonhemophiliacs with Factor VIII Autoantibodies. Recombinate and Kogenate Study Groups","volume":"89","author":"Prescott","year":"1997","journal-title":"Blood"},{"key":"ref_46","unstructured":"Paul, G. (2023, May 14). Acquired Hemophilia. Treatment of Hemophilia, World Federation of Hemophilia, 2012. No. 38. Available online: https:\/\/www1.wfh.org\/publications\/files\/pdf-1186.pdf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1046\/j.1538-7836.2003.00251.x","article-title":"Human CD4+ T-Cell Epitope Repertoire on the C2 Domain of Coagulation Factor VIII","volume":"1","author":"Reding","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1538-7836.2004.00850.x","article-title":"Epitope Repertoire of Human CD4+ T Cells on the A3 Domain of Coagulation Factor VIII","volume":"2","author":"Reding","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"697602","DOI":"10.3389\/fimmu.2021.697602","article-title":"Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor","volume":"12","author":"Ronayne","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2022008071","article-title":"Targets of Autoantibodies in Acquired Hemophilia A Are Not Restricted to Factor VIII: Data from the GTH-AH 01\/2010 Study","volume":"7","author":"Oleshko","year":"2023","journal-title":"Blood Adv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2147\/JBM.S342077","article-title":"Acquired Haemophilia A: A Review of What We Know","volume":"13","author":"Marco","year":"2022","journal-title":"J. Blood Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2011.08890.x","article-title":"Do Proteolytic Antibodies Complete the Panoply of the Autoimmune Response in Acquired Haemophilia A?","volume":"156","author":"Mahendra","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7714","DOI":"10.4049\/jimmunol.180.11.7714","article-title":"Factor VIII Hydrolysis Mediated by Anti-Factor VIII Autoantibodies in Acquired Hemophilia","volume":"180","author":"Wootla","year":"2008","journal-title":"J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.febslet.2009.07.009","article-title":"Factor VIII-Hydrolyzing IgG in Acquired and Congenital Hemophilia","volume":"583","author":"Wootla","year":"2009","journal-title":"FEBS Lett."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2010-07-296103","article-title":"Proteolytic Antibodies Activate Factor IX in Patients with Acquired Hemophilia","volume":"117","author":"Wootla","year":"2011","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2516.2008.01976.x","article-title":"HLA Genotype in Patients with Acquired Haemophilia A","volume":"16","author":"Pavlova","year":"2010","journal-title":"Haemophilia"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1034\/j.1399-0039.2001.580608.x","article-title":"Combination of HLA-A and HLA Class II Alleles Controls the Susceptibility to Rheumatoid Arthritis","volume":"58","author":"Tsuchiya","year":"2001","journal-title":"Tissue Antigens"},{"key":"ref_58","first-page":"1","article-title":"Associations between HLA Class II Alleles and Type 1 Diabetes Mellitus in the Slovak Population","volume":"40","author":"Buc","year":"2006","journal-title":"Endocr. Regul."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0038-1655944","article-title":"HLA Class II Profile: A Weak Determinant of Factor VIII Inhibitor Development in Severe Haemophilia A. UKHCDO Inhibitor Working Party","volume":"77","author":"Hay","year":"1997","journal-title":"Thromb. Haemost."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0038-1655945","article-title":"HLA Genotype of Patients with Severe Haemophilia A Due to Intron 22 Inversion with and without Inhibitors of Factor VIII","volume":"77","author":"Oldenburg","year":"1997","journal-title":"Thromb. Haemost."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Pardos-Gea, J., Martin-Fernandez, L., Closa, L., Ferrero, A., Marzo, C., Rubio-Rivas, M., Mitjavila, F., Gonz\u00e1lez-Porras, J.R., Bastida, J.M., and Mateo, J. (2023). Key Genes of the Immune System and Predisposition to Acquired Hemophilia A: Evidence from a Spanish Cohort of 49 Patients Using Next-Generation Sequencing. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216372"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2516.2006.01361.x","article-title":"Genetic Risk Factors for Inhibitors to Factors VIII and IX","volume":"12","author":"Oldenburg","year":"2006","journal-title":"Haemophilia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5045\/kjh.2011.46.1.49","article-title":"Identification of a Shared F8 Mutation in the Korean Patients with Acquired Hemophilia A","volume":"46","author":"Hwang","year":"2011","journal-title":"Korean J. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00277-009-0887-3","article-title":"Acquired Haemophilia Caused by Non-Haemophilic Factor VIII Gene Variants","volume":"89","author":"Tiede","year":"2010","journal-title":"Ann. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1538-7836.2007.02290.x","article-title":"Polymorphisms in the CTLA-4 Gene and Inhibitor Development in Patients with Severe Hemophilia A","volume":"5","author":"Astermark","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2516.2007.01618.x","article-title":"Increased Frequency of the CTLA-4 49 A\/G Polymorphism in Patients with Acquired Haemophilia A Compared to Healthy Controls","volume":"14","author":"Pavlova","year":"2008","journal-title":"Haemophilia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","article-title":"Association of the T-Cell Regulatory Gene CTLA4 with Susceptibility to Autoimmune Disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2567.2010.03360.x","article-title":"Natural Killer Cells in Human Autoimmune Diseases","volume":"131","author":"Schleinitz","year":"2010","journal-title":"Immunology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2567.2009.03045.x","article-title":"Natural Killer Cells: Integrating Diversity with Function","volume":"126","author":"Cheent","year":"2009","journal-title":"Immunology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molimm.2009.02.023","article-title":"The Role of the Activating Receptor NKG2D in Autoimmunity","volume":"47","year":"2009","journal-title":"Mol. Immunol."},{"key":"ref_71","unstructured":"Al Aboud, N.M., Tupper, C., and Jialal, I. (2024). StatPearls [Internet], StatPearls Publishing."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of Chromatin by Histone Modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41580-022-00566-8","article-title":"Long Non-Coding RNAs: Definitions, Functions, Challenges and Recommendations","volume":"24","author":"Mattick","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(08)60678-8","article-title":"5-Methylcytosine, Gene Regulation, and Cancer","volume":"40","author":"Riggs","year":"1983","journal-title":"Adv. Cancer Res."},{"key":"ref_75","unstructured":"Haider, M.Z., and Anwer, F. (2023, May 14). Acquired Hemophilia, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560494\/."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.thromres.2020.11.016","article-title":"Rise of Levels of von Willebrand Factor and Factor VIII with Age: Role of Genetic and Acquired Risk Factors","volume":"197","author":"Biguzzi","year":"2021","journal-title":"Thromb. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3389\/fgene.2019.00508","article-title":"F8 Inversions at Xq28 Causing Hemophilia A Are Associated With Specific Methylation Changes: Implication for Molecular Epigenetic Diagnosis","volume":"10","author":"Jamil","year":"2019","journal-title":"Front. Genet."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1055\/s-0037-1619797","article-title":"Methylation Analysis of the Promoter Region and Intron 1 of the Factor VIII Gene in Haemophilia A Patients","volume":"33","author":"Zimmermann","year":"2013","journal-title":"Hamostaseologie"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/trf.15605","article-title":"Clinical Manifestation of Hemophilia A in the Absence of Mutations in the F8 Gene That Encodes FVIII: Role of MicroRNAs","volume":"60","author":"Jankowska","year":"2020","journal-title":"Transfusion"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/jcmm.17741","article-title":"RNA Sequencing Suggests That Non-Coding RNAs Play a Role in the Development of Acquired Haemophilia","volume":"27","author":"Tigu","year":"2023","journal-title":"J. Cell. Mol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e7773","DOI":"10.1002\/ccr3.7773","article-title":"Fasciotomy on a Female Patient with Acquired Factor VIII: A Case Report and Literature Review of Management","volume":"11","author":"Lovell","year":"2023","journal-title":"Clin. Case Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"108999","DOI":"10.1016\/j.ijscr.2023.108999","article-title":"Treatment of a Compartment Syndrome in the Leg in an Elderly Patient with Acquired Hemophilia Type A: A Case Report","volume":"112","author":"Fonseca","year":"2023","journal-title":"Int. J. Surg. Case Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/23320885.2022.2071274","article-title":"Acute Forearm Compartment Syndrome in the Setting of Acquired Hemophilia A","volume":"9","author":"Adeclat","year":"2022","journal-title":"Case Rep. Plast. Surg. Hand Surg."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0609.1998.tb01103.x","article-title":"Early Treatment with Recombinant Factor VIIa Results in Greater Efficacy with Less Product","volume":"63","author":"Lusher","year":"1998","journal-title":"Eur. J. Haematol. Suppl."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Sridharan, M., and Pruthi, R.K. (2022). Autoimmune (Acquired) Hemophilia: Updates in Diagnosis and Therapy. Hematologist, 19.","DOI":"10.1182\/hem.V19.2.2022214"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of Bleeding in Acquired Hemophilia A: Results from the European Acquired Haemophilia (EACH2) Registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and Safety of OBI-1, an Antihaemophilic Factor VIII (Recombinant), Porcine Sequence, in Subjects with Acquired Haemophilia A","volume":"21","author":"Greist","year":"2015","journal-title":"Haemophilia"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00277-018-3372-z","article-title":"Lessons from a Systematic Literature Review of the Effectiveness of Recombinant Factor VIIa in Acquired Haemophilia","volume":"97","author":"Tiede","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/ejh.13853","article-title":"Activated Prothrombin Complex Concentrate to Treat Bleeding Events in Acquired Hemophilia A: BAHAS Study","volume":"109","author":"Marco","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_90","first-page":"CD011441","article-title":"Bypassing Agent Prophylaxis in People with Hemophilia A or B with Inhibitors","volume":"9","author":"Nevitt","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/jth.14784","article-title":"Laboratory Testing in Hemophilia: Impact of Factor and Non-Factor Replacement Therapy on Coagulation Assays","volume":"18","author":"Peyvandi","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e12688","DOI":"10.1002\/rth2.12688","article-title":"Recombinant Porcine Factor VIII in Acquired Hemophilia A: Experience from Two Patients and Literature Review","volume":"6","author":"Hayden","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1538-7836.2012.04793.x","article-title":"Mechanisms and Monitoring of Bypassing Agent Therapy","volume":"10","author":"Hoffman","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/hae.14902","article-title":"Coagulation Potentials of Plasma-Derived Factors VIIa and X Mixture (Byclot\u00ae) Evaluated by Global Coagulation Assay in Patients with Acquired Haemophilia A","volume":"30","author":"Takeyama","year":"2024","journal-title":"Haemophilia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s40265-019-01200-2","article-title":"Emicizumab: A Review in Haemophilia A","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.farma.2023.10.002","article-title":"Utilization of Emicizumab in the Treatment of a Case of Acquired Hemophilia A","volume":"48","year":"2024","journal-title":"Farm. Hosp."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e870","DOI":"10.1016\/S2352-3026(23)00303-4","article-title":"Rapidly Loading Emicizumab without Immunosuppression in Acquired Haemophilia","volume":"10","author":"Ragni","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/jha2.878","article-title":"Emicizumab for Acquired Hemophilia A: Report of Two Cases and Dosing Strategies","volume":"5","author":"Ahmed","year":"2024","journal-title":"eJHaem"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Franchini, M., and Focosi, D. (2024). Innovative Therapies for Acquired Hemophilia A. Semin. Thromb. Hemost., Online ahead of print.","DOI":"10.1055\/s-0044-1779737"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic Factors for Remission of and Survival in Acquired Hemophilia A (AHA): Results from the GTH-AH 01\/2010 Study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"102318","DOI":"10.1016\/j.rpth.2024.102318","article-title":"Acquired Hemophilia A: A Single-Center Study of 165 Patients","volume":"8","author":"Yu","year":"2024","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Papalexandri, A., Gavriilaki, E., Vardi, A., Kotsiou, N., Demosthenous, C., Constantinou, N., Touloumenidou, T., Zerva, P., Kika, F., and Iskas, M. (2023). Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216029"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1226114","DOI":"10.3389\/fmed.2023.1226114","article-title":"Caplacizumab for Immune Thrombotic Thrombocytopenic Purpura: Real-World Multicenter Data","volume":"10","author":"Gavriilaki","year":"2023","journal-title":"Front. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/03630269.2018.1540353","article-title":"Successful Outcome of Hyperhemolysis in Sickle Cell Disease Following Multiple Lines of Treatment: The Role of Complement Inhibition","volume":"42","author":"Vlachaki","year":"2018","journal-title":"Hemoglobin"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ajh.27128","article-title":"Single-Dose Rituximab plus Glucocorticoid versus Cyclophosphamide plus Glucocorticoid in Patients with Newly Diagnosed Acquired Hemophilia A: A Multicenter, Open-Label, Randomized Noninferiority Trial","volume":"99","author":"Wang","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.reuma.2014.09.003","article-title":"Severe Infections in Patients with Autoimmune Diseases Treated with Cyclophosphamide","volume":"11","author":"Cavallasca","year":"2015","journal-title":"Reumatol. Clin."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0190-9622(18)30747-3","article-title":"Rediscovering Mycophenolic Acid: A Review of Its Mechanism, Side Effects, and Potential Uses","volume":"37","author":"Kitchin","year":"1997","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/00003495-199142050-00005","article-title":"Cyclophosphamide Toxicity. Characterising and Avoiding the Problem","volume":"42","author":"Fraiser","year":"1991","journal-title":"Drugs"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/s41409-018-0395-y","article-title":"BEAC (Carmustine, Etoposide, Cytarabine, and Cyclophosphamide) in Autologous Hematopoietic Cell Transplantation: A Safe and Effective Alternative Conditioning Regimen for Hodgkin and Non-Hodgkin Lymphoma","volume":"54","author":"Sakellari","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00277-018-3383-9","article-title":"Long-Term Outcomes of Total Body Irradiation plus Cyclophosphamide versus Busulfan plus Cyclophosphamide as Conditioning Regimen for Acute Lymphoblastic Leukemia: A Comparative Study","volume":"97","author":"Sakellari","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"100907","DOI":"10.1016\/j.blre.2021.100907","article-title":"Unexplained Hemorrhagic Syndrome? Consider Acquired Hemophilia A or B","volume":"53","author":"Constantinescu","year":"2022","journal-title":"Blood Rev."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s43162-021-00074-9","article-title":"Acquired Hemophilia A (AHA): Underreported, Underdiagnosed, Undertreated Medical Condition","volume":"34","author":"Ayad","year":"2022","journal-title":"Egypt. J. Intern. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/MBC.0b013e32832ca388","article-title":"The Prognosis and Treatment of Acquired Hemophilia: A Systematic Review and Meta-Analysis","volume":"20","author":"Bitting","year":"2009","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.thromres.2023.11.025","article-title":"Characteristics and Outcome of a Territory-Wide Cohort Study of Patients with Acquired Hemophilia A in Hong Kong","volume":"233","author":"Sin","year":"2024","journal-title":"Thromb. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"E416","DOI":"10.1002\/ajh.26323","article-title":"The International Hemoglobinopathy Research Network (INHERENT): An International Initiative to Study the Role of Genetic Modifiers in Hemoglobinopathies","volume":"96","author":"Kountouris","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Evangelidis, P., Venou, T.-M., Fani, B., Vlachaki, E., Gavriilaki, E., and on behalf of the International Hemoglobinopathy Research Network (INHERENT) (2023). Endocrinopathies in Hemoglobinopathies: What Is the Role of Iron?. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216263"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Lazaridis, A., Gavriilaki, E., Douma, S., and Gkaliagkousi, E. (2021). Toll-Like Receptors in the Pathogenesis of Essential Hypertension. A Forthcoming Immune-Driven Theory in Full Effect. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073451"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1182\/blood.2021012860","article-title":"Advancing Therapeutic Complement Inhibition in Hematologic Diseases: PNH and Beyond","volume":"139","author":"Gavriilaki","year":"2022","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/ejh.12689","article-title":"Acquired Haemophilia: An Overview for Clinical Practice","volume":"95","author":"Kessler","year":"2015","journal-title":"Eur. J. Haematol."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/6\/309\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:47:02Z","timestamp":1760107622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/6\/309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":119,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["cimb46060309"],"URL":"https:\/\/doi.org\/10.3390\/cimb46060309","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]}}}